Wall Street analysts expect that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce earnings of $0.60 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Integra Lifesciences’ earnings, with the highest EPS estimate coming in at $0.61 and the lowest estimate coming in at $0.59. Integra Lifesciences reported earnings of $0.45 per share during the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The business is scheduled to announce its next earnings results on Wednesday, July 25th.
On average, analysts expect that Integra Lifesciences will report full-year earnings of $2.41 per share for the current financial year, with EPS estimates ranging from $2.38 to $2.44. For the next financial year, analysts forecast that the company will report earnings of $2.74 per share, with EPS estimates ranging from $2.68 to $2.78. Zacks’ EPS averages are an average based on a survey of analysts that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.09. Integra Lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The firm had revenue of $357.10 million during the quarter, compared to the consensus estimate of $349.15 million. During the same period in the previous year, the firm posted $0.39 EPS. The company’s quarterly revenue was up 38.1% compared to the same quarter last year.
Several research analysts recently issued reports on IART shares. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research report on Wednesday, April 25th. Jefferies Financial Group restated a “buy” rating and set a $63.00 price objective on shares of Integra Lifesciences in a research report on Thursday, March 1st. BidaskClub upgraded Integra Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, March 23rd. Zacks Investment Research upgraded Integra Lifesciences from a “hold” rating to a “buy” rating and set a $69.00 price objective for the company in a research report on Tuesday, May 1st. Finally, Morgan Stanley lifted their price objective on Integra Lifesciences from $53.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 26th. Twelve analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Integra Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $60.69.
Shares of Integra Lifesciences stock traded up $1.36 during trading on Friday, hitting $65.77. 692,655 shares of the company were exchanged, compared to its average volume of 738,635. The company has a debt-to-equity ratio of 1.77, a current ratio of 2.53 and a quick ratio of 1.66. Integra Lifesciences has a fifty-two week low of $41.51 and a fifty-two week high of $67.50. The company has a market capitalization of $5.71 billion, a P/E ratio of 33.90, a P/E/G ratio of 1.95 and a beta of 0.65.
In other Integra Lifesciences news, VP Daniel L. Reuvers sold 1,000 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $66.97, for a total value of $66,970.00. Following the transaction, the vice president now owns 25,009 shares in the company, valued at approximately $1,674,852.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of IART. Westwood Holdings Group Inc. acquired a new position in Integra Lifesciences in the 1st quarter worth $32,180,000. Champlain Investment Partners LLC lifted its holdings in Integra Lifesciences by 7.6% in the 1st quarter. Champlain Investment Partners LLC now owns 4,997,595 shares of the life sciences company’s stock worth $276,567,000 after buying an additional 351,520 shares in the last quarter. BlackRock Inc. lifted its holdings in Integra Lifesciences by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,135,552 shares of the life sciences company’s stock worth $389,367,000 after buying an additional 269,484 shares in the last quarter. Broadfin Capital LLC raised its stake in shares of Integra Lifesciences by 321.1% in the 4th quarter. Broadfin Capital LLC now owns 330,600 shares of the life sciences company’s stock valued at $15,823,000 after purchasing an additional 252,100 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Integra Lifesciences by 92.4% in the 4th quarter. Renaissance Technologies LLC now owns 405,800 shares of the life sciences company’s stock valued at $19,422,000 after purchasing an additional 194,900 shares in the last quarter. Hedge funds and other institutional investors own 79.49% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Get a free copy of the Zacks research report on Integra Lifesciences (IART)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.